0
GENFIT S.A. Banner Image

GENFIT S.A. has reached its limit for free report views

Work for GENFIT S.A.? Upgrade Your Profile and unlock all your annual reports.

GENFIT S.A.

  • Ticker GNFT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
GENFIT S.A. Logo Image
  • 51-200 Employees
  • Based in Loos, France
GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT plans to initiate a Phase 3 clinical trial of elafibranor in patients with PBC. As part of GENFIT’sMore comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4™, a new, non-invasive blood-based diagnostic technology which, if approved, could enable easier identification of patients with at-risk NASH. With facilities in Lille and Paris, France, and Cambridge, MA, USA, the Company has approximately 200 employees. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT).
GENFIT S.A.

Most Recent Annual Report

GENFIT S.A. MOST RECENT 2019 Annual Report

Report Locked. GENFIT S.A. has reached its limit for free report views.